in this issue
Regions :: North America :: U.S.
AstraZeneca acquires specialty pharma company Omthera for $323 million
9:05 AM MDT | May 28, 2013 | Natasha Alperowicz
AstraZeneca today announced that it has agreed to acquire Omthera Pharmaceuticals (Princeton, NJ), a specialty pharmaceutical company focused on the development and commercialization of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia. Omthera’s Epanova, an investigational product for the potential treatment of patients with very high triglycerides, is a novel omega-3 free fatty acid composition that has been shown to bolster levels of eicosapentaenoic acid and docosahexaenoic acid significantly in the blood, the...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee